Sechenov Researchers Report Non-Viral CRISPR Strategy Aiming to Cure Hepatitis B

Overview

• The team describes a CRISPR/Cas9 therapy candidate that targets hepatitis B viral DNA using biodegradable, non-viral nanoparticles designed to evade immune recognition.
• Researchers report roughly 80% packaging efficiency with 200–250 CRISPR complexes per particle, which they say is sufficient to attack all copies of the viral genome inside an infected cell.
• According to their data, the particles reach 90–95% of infected cells and leave no detectable traces in the liver after 20–24 hours.
• Investigators say foundational preclinical studies have shown efficacy and safety, and they characterize the program as moving into translational stages.
• The group contends the approach could enable curative therapy where current drugs only suppress replication, while noting that independent validation, peer review, and formal clinical trials are still required before patient use.